3-异硫代氰酰基乙酰苯胺 | 3137-83-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-异硫代氰酰基乙酰苯胺
• 中文别名: N-(3-异硫氰基苯基)醋胺石
• 英文名称: meta-acetamidophenyl isothiocyanate
• 英文别名: N-(3-isothiocyanatophenyl)acetamide；1-Acetamino-3-isothiocyanato-benzol；3-Acetylamino-phenylisothiocyanat；3-Acetamino-phenylisothiocyanat
• CAS: 3137-83-5
• 化学式: C₉H₈N₂OS
• mdl: MFCD00143015
• 分子量: 192.241
• InChiKey: HLWVGQKSSIHUAX-UHFFFAOYSA-N

物化性质

• 熔点：
  156-157 °C
• 沸点：
  417.0±28.0 °C(Predicted)
• 密度：
  1.2535 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  73.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2930909090

SDS

N-(3-异硫氰酸根合苯基)乙酰胺MSDS英文版

反应信息

• 作为反应物：
  描述：

  3-异硫代氰酰基乙酰苯胺 在 氨 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 1.0h， 生成 N-(3-((4-(3,4-dihydroxyphenyl)thiazol-2-yl)amino)phenyl)acetamide
  参考文献：
  名称：

  Synthesis and in-vitro evaluation of 2-amino-4-arylthiazole as inhibitor of 3D polymerase against foot-and-mouth disease (FMD)

  摘要：

  Foot-and-mouth disease (FMD) is a highly contagious vesicular disease of livestock caused by a highly variable RNA virus, foot-and-mouth disease virus (FMDV). One of the targets to suppress expansion of and to control FMD is 3D polymerase (FMDV 3Dpol). In this study, 2-amino-4-arylthiazole derivatives were synthesized and evaluated for their inhibitory activity against FMDV 3Dpol. Among them, compound 20i exhibited the most potent functional inhibition (IC50 = 039 mu M) of FMDV 3D polymerase and compound 24a (EC50 = 13.09 mu M) showed more potent antiviral activity than ribavirin (EC50 = 1367 mu M) and T1105 (EC50 = 347 mu M) with IBRS-2 cells infected by the FMDV O/SKR/2010 strain. (C) 2015 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2015.08.020
• 作为产物：
  描述：

  间苯二胺 在 溶剂黄146 、 三乙胺 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 3-异硫代氰酰基乙酰苯胺
  参考文献：
  名称：

  Synthesis and in-vitro evaluation of 2-amino-4-arylthiazole as inhibitor of 3D polymerase against foot-and-mouth disease (FMD)

  摘要：

  Foot-and-mouth disease (FMD) is a highly contagious vesicular disease of livestock caused by a highly variable RNA virus, foot-and-mouth disease virus (FMDV). One of the targets to suppress expansion of and to control FMD is 3D polymerase (FMDV 3Dpol). In this study, 2-amino-4-arylthiazole derivatives were synthesized and evaluated for their inhibitory activity against FMDV 3Dpol. Among them, compound 20i exhibited the most potent functional inhibition (IC50 = 039 mu M) of FMDV 3D polymerase and compound 24a (EC50 = 13.09 mu M) showed more potent antiviral activity than ribavirin (EC50 = 1367 mu M) and T1105 (EC50 = 347 mu M) with IBRS-2 cells infected by the FMDV O/SKR/2010 strain. (C) 2015 Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2015.08.020

文献信息

• Nitrogen-containing heterocyclic compounds
  申请人：——

  公开号：US20020068734A1

  公开（公告）日：2002-06-06

  The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of PDGF receptor to hinder abnormal cell growth and cell wandering and thus are useful for the prevention or treatment of cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis. The compounds are represented by general formula (I): 1 wherein V represents an oxygen atom or a sulfur atom; W represents 1,4-piperazinediyl or 1,4-homopiperazinediyl in which carbons on the ring may be substituted by unsubstituted alkyl groups; X represents a nitrogen atom or C-R 9 ; Y represents a nitrogen atom or C-R 8 ; Z represents a nitrogen atom or C-R 7 (provided that at least one of X, Y and Z represents a nitrogen atom); R 1 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alicyclic alkyl group, etc.; R 2 represents a substituted alkyl group, a substituted or unsubstituted alicyclic alkyl group, etc.; R 3 , R 4 , R 5 and R 6 , which may be the same or different, each represents a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a nitro group, a cyano group, OR 12 , —NR 15 R 16 , etc.; R 7 represents a halogen atom, etc.; R 8 has the same significance as R 7 , and R 9 represents a hydrogen atom or —COR 41 .

  本发明提供了含氮杂环化合物及其药学上可接受的盐，其抑制PDGF受体的磷酸化，以阻碍异常细胞生长和细胞游走，因此可用于预防或治疗细胞增殖性疾病，如动脉硬化、血管再狭窄、癌症和肾小球硬化。所述化合物由通式（I）表示：其中V表示氧原子或硫原子；W表示1,4-哌嗪基或1,4-同源哌嗪基，其中环上的碳可以被未取代的烷基取代；X表示氮原子或C-R9；Y表示氮原子或C-R8；Z表示氮原子或C-R7（前提是X、Y和Z中至少有一个表示氮原子）；R1表示氢原子、取代或未取代的烷基、取代或未取代的脂环烷基等；R2表示取代的烷基、取代或未取代的脂环烷基等；R3、R4、R5和R6，可以相同也可以不同，每个表示氢原子、卤素原子、取代或未取代的烷基、硝基、氰基、OR12、—NR15R16等；R7表示卤素原子等；R8具有与R7相同的意义，且R9表示氢原子或—COR41。
• Arylamino Purine Derivatives, Preparation Method and Pharmaceutical Use Thereof
  申请人：Yang Shengyong

  公开号：US20130203986A1

  公开（公告）日：2013-08-08

  Arylamino purine derivatives represented by formula I and their preparation method are disclosed, wherein each substituent is defined as in the description. The derivatives have an inhibitory effect on non-small cell lung cancer with deletion mutation of exon 19 or L858R point mutation of exon 21 in epidermal growth factor receptor (EGFR).

  公开了由公式I所代表的芳基氨基嘌呤衍生物及其制备方法，其中每个取代基在说明书中有定义。这些衍生物对于表皮生长因子受体（EGFR）的外显子19缺失突变或外显子21的L858R点突变所致的非小细胞肺癌具有抑制作用。
• Process and intermediates for the preparation of substituted 6-(3,5,6,7-tetrahydropyrrolo-[2,1-c][1,2,4]-thiadiazol-3-ylidenimino)-7-fluoro-2H-1,4-benzoxazin-3(4H)-ones
  申请人：SCHERING AKTIENGESELLSCHAFT

  公开号：EP0448188A2

  公开（公告）日：1991-09-25

  The invention relates a new process for the preparation of substituted 6-(3,5,6,7-tetrahydropyrrolo[2,1-c][1,2,4]-thiadiazol-3-ylidenimino)-7-fluoro-2H-1,4-benzoxazin-3(4H)-ones of general formula I in which R¹ is C₁-C₆-alkyl, C₂-C₆-alkenyl or C₃-C₆-alkynyl, and R² and R³, which may be the same or different, are hydrogen or C₁-C₄-alkyl, which starts from the known a 2-amino-5-fluorophenol of formula II via the new acetanilide of formula IV in which R is hydrogen or chlorine, via the new 5-nitroacetanilide of formula V via the new 5-aminoacetanilide of formula VI via the new 5-isothiocyanatoacetanilide of formula VIII via the known benzoxazinone isothiocyanate of general formula IX and via the known iminothiadiazole of general formula XI

  本发明涉及一种制备通式 I 的取代 6-(3,5,6,7-四氢吡咯并[2,1-c][1,2,4]-噻二唑-3-亚基亚氨基)-7-氟-2H-1,4-苯并恶嗪-3(4H)-酮的新工艺 其中 R¹ 是 C₁-C₆-烷基、C₂-C₆-烯基或 C₃-C₆-炔基，以及 R² 和 R³ 可以相同或不同，均为氢或 C₁-C₄ 烷基、 从已知的 式 II 的 2-氨基-5-氟苯酚 通过式 IV 的新乙酰苯胺 其中 R 为氢或氯、 通过式 V 的新 5-硝基乙酰苯胺 通过式 VI 的新 5-氨基乙酰苯胺 通过式 VIII 的新 5-异硫氰酸基乙酰苯胺 通过通式 IX 的已知苯并噁嗪酮异硫氰酸酯 和通式 XI 的已知亚氨基噻二唑
• NITROGENOUS HETEROCYCLIC COMPOUNDS
  申请人：KYOWA HAKKO KOGYO KABUSHIKI KAISHA

  公开号：EP0882717A1

  公开（公告）日：1998-12-09

  The present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of PDGF receptor to hinder abnormal cell growth and cell wandering and thus are useful for the prevention or treatment of cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis. The compounds are represented by general formula (I): wherein V represents an oxygen atom or a sulfur atom; W represents 1,4-piperazinediyl or 1,4-homopiperazinediyl in which carbons on the ring may be substituted by unsubstituted alkyl groups; X represents a nitrogen atom or C-R9; Y represents a nitrogen atom or C-R8; Z represents a nitrogen atom or C-R7 (provided that at least one of X, Y and Z represents a nitrogen atom); R1 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alicyclic alkyl group, etc.; R2 represents a substituted alkyl group, a substituted or unsubstituted alicyclic alkyl group, etc.; R3, R4, R5 and R6, which may be the same or different, each represents a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group, a nitro group, a cyano group, - OR12, -NR15R16, etc.; R7 represents a halogen atom, etc.; R8 has the same significance as R7, and R9 represents a hydrogen atom or -COR41.

  本发明提供了含氮杂环化合物及其药学上可接受的盐类，它们能抑制 PDGF 受体的磷酸化，从而阻碍细胞的异常生长和游走，因此可用于预防或治疗细胞增殖性疾病，如动脉硬化、血管再阻塞、癌症和肾小球硬化症。这些化合物由通式 (I) 表示： 其中 V 代表氧原子或硫原子； W 代表 1,4-哌嗪二基或 1,4-高哌嗪二基，其中环上的碳可被未取代的烷基取代； X 代表氮原子或 C-R9； Y 代表氮原子或 C-R8 Z 代表氮原子或 C-R7（条件是 X、Y 和 Z 中至少有一个代表氮原子）； R1 代表氢原子、取代或未取代的烷基、取代或未取代的脂环烷基等； R2 代表取代的烷基、取代或未取代的脂环烷基等； R3、R4、R5 和 R6 可以相同或不同，各自代表氢原子、卤素原子、取代或未取代的烷基、硝基、氰基、- OR12、-NR15R16 等； R7 代表卤素原子等； R8 与 R7 意义相同，以及 R9 代表氢原子或-COR41。
• ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF
  申请人：Si Chuan University

  公开号：EP2578584B1

  公开（公告）日：2020-08-12